武田药品有限企业（Takeda Pharmaceutical Company Limited，TYO：4502）成立于1925年1月29日，总部位于大阪，注册资本为635亿日元。根据2012年IMS的销售额数据，武田药品是日本最大的制药企业，是全球制药和消费者保健行业居于领先地位的跨国集团。企业秉承“为世界人民的健康和健康的生活做贡献”的经营理念，致力于药品的研究开发，企业在日本、美国和欧洲先后建立研发中心，营销网络遍及欧洲、美洲、亚洲的紧要国家，药品销售到全球90多个国家地区。

企业的紧要产品有：

• 兰索拉唑(lansooprazole，Prevacid)
• 亮丙瑞林(leuprorelin，Leuplin)
• 伏格列波糖 (voglibose，Basen)
• 头孢替安(cefotiam，Pansporin)
• 口服抗糖尿病药吡格拉酮 (pioglitaznone，Actos)
• 血管紧张素Ⅱ拮抗剂坎伐沙坦(candesartan)

天津武田药品有限企业

天津武田药品有限企业是日本武田药品株式会社与原天津力生制药厂，现天津力生制药有限企业合资兴建的现代化制药企业。企业成立于1996年8月28日，总投入额2620万美元，注册资本1920万美元，其中外方占75%，中方占25%。在全国设有10个办事机构，营销网络覆盖中国紧要市场。

台湾武田药品工业企业

台湾武田药品工业企业创立于民国51年，是武田药品重要的海外分支机构之一。自企业创立以来，台湾武田就秉持着『为贡献人类的健康及高品质生活』之经营理念，持续引进优越的新处方药品，积极提升了台湾社会人群之福祉。除了行销台湾地区以外，台湾武田也于民国90年成立香港分企业，将成为港澳地区的优良药品企业。

Takeda Pharmaceutical Company Limited (TYO: 4502) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company, employing over 19,000 employees and achieving $15.7 billion USD in revenue during the 2008 fiscal year. The company is focused on metabolic disorders, gastroenterology, central nervous system disorders, inflammation, as well as oncology through its independent subsidiary

Takeda Pharmaceuticals was first founded on June 12, 1781 and was incorporated on January 29, 1925.

In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launch blockbusters Lupron (leuprolide) in 1985 and Prevacid (lansoprazole) in 1995.

One of the firm's mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of Type 2 Diabetes. Launched in 1999 by Takeda's newly formed American subsidiary at the time distinct from TAP, Takeda Pharmaceuticals North America, and formerly co-marketed with Eli Lilly, Actos has become the best-selling diabetes drug in the world with $4 billion USD in sales during the 2008 fiscal year.

In February 2005, Takeda announced its acquisition of San Diego, CA-based Syrrx, a company specializing in high-throughput X-ray crystallography, for $270 million.

In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market.

In March 2008, Takeda and Abbott Laboratories announced plans to conclude their highly successful 30-year old joint venture TAP Pharmaceuticals that had over $3 billion in sales in its final year. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. On the other hand, Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees.

In April 2008, Takeda announced that it was acquiring Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for $8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas.

In May 2008, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.

Some of the key products that Takeda produces or markets on behalf of partners include:

• Actos (pioglitazone) - Type 2 Diabetes
• Amitiza (lubiprostone) - Chronic idiopathic constipation
• Basen (voglibose) - Type 2 Diabetes
• Benet (risedronic acid) - Osteoporosis (Japan)
• Blopress (candesartan) - Hypertension
• Enbrel (etanercept) - Inflammatory diseases (Japan)
• Kapidex (dexlansoprazole) - Gastroesophageal reflux disease
• Lupron/Leuplin (leuprorelin) - GnRH agonist for prostate cancer and endometriosis
• Prevacid/Takepron (lansoprazole) - Gastroesophageal reflux disease
• Rozerem (ramelteon) - Insomnia
• Uloric (febuxostat) - Gout
• Velcade (bortezomib) - Multiple myeloma & mantle cell lymphoma (Millennium Pharmaceuticals)